相关实验视频

Updated: Jun 23, 2026

Behavioral Assessment of Visual Function via Optomotor Response and Cognitive Function via Y-Maze in Diabetic Rats

Behavioral Assessment of Visual Function via Optomotor Response and Cognitive Function via Y-Maze in Diabetic Rats

Published on: October 23, 2020

针对RAGE-RIPK1结合部位减轻了与糖尿病相关的认知缺陷

Lin Gao¹, Shidi Wu¹, Bin Hu^2,3

¹The Graduate School, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, China.

Journal of neuroinflammation

|June 21, 2025

概括

糖尿病通过微质激活损害认知能力. 针对大脑中的RAGE-RIPK1相互作用,可以减少神经炎症,防止认知缺陷,提供一种新的治疗策略.

科学领域:

神经科学是一个神经科学.
免疫学免疫学免疫学
内分泌学在内分泌学.

背景情况:

微质激活驱动神经炎症,导致糖尿病的认知缺陷.
与受体相互作用蛋白激酶1 (RIPK1) 酸化有关,但其在糖尿病认知障碍中的确切作用尚不清楚.

研究的目的:

阐明RIPK1,RAGE和糖尿病相关认知缺陷中的微质激活之间的分子机制.
研究一种针对RAGE-RIPK1相互作用的新型治疗策略.

主要方法:

在患有认知障碍的糖尿病患者中评估RIPK1表达.
利用糖尿病小鼠模型检查微质中的RIPK1-RAGE相互作用.
使用针对大脑的RIPK1来阻止RAGE-RIPK1复合体.

主要成果:

在患有糖尿病认知障碍的患者和小鼠中,RIPK1表达升高.
RIPK1死亡域直接与RAGE (ctRAGE) 的C终端结合,调节微质中的RIPK1酸化.
该RAGE-RIPK1复合体激活炎症通路,加剧认知缺陷.
该RIPK1抑制了RIPK1酸化,减少了神经炎症,并改善了神经元功能,防止了认知能力下降.

结论:

一种涉及微质中的RAGE-RIPK1相互作用的新机制有助于神经炎症和糖尿病认知障碍.
通过脑透性来准这种RAGE-RIPK1通路,为高血糖引起的认知缺陷提供了一个有前途的治疗方法.

关键词:

与糖尿病相关的认知缺陷神经炎症是一种神经炎症.这是一种RIPK1.与受体相互作用的蛋白激酶1受体相互作用先进的糖化最终产品的受体.

更多相关视频

Retinal Pathophysiological Evaluation in a Rat Model

Retinal Pathophysiological Evaluation in a Rat Model

Published on: May 6, 2022

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Published on: April 7, 2023

相关概念视频

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

Type I Diabetes II: Pathophysiology

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...

Hypoglycemia

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...

Diabetic Retinopathy

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...